METOPROLOL SUCCINATE Drug Patent Profile
✉ Email this page to a colleague
When do Metoprolol Succinate patents expire, and when can generic versions of Metoprolol Succinate launch?
Metoprolol Succinate is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Actavis Labs Fl Inc, Alkem Labs Ltd, Cipla, Dr Reddys Labs Ltd, Granules, Hetero Labs Ltd Iii, Ipca Labs Ltd, Lupin, Mylan Pharms Inc, Nesher Pharms, Novast Labs, Pharmadax, Prinston Inc, Reddys, Sandoz, Sunshine, Visum Pharm, Wockhardt Bio Ag, Yichang Humanwell, Zhejiang Jutai Pharm, and Zydus Pharms. and is included in twenty-eight NDAs.
The generic ingredient in METOPROLOL SUCCINATE is metoprolol succinate. There are sixty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the metoprolol succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metoprolol Succinate
A generic version of METOPROLOL SUCCINATE was approved as metoprolol succinate by ACTAVIS LABS FL INC on August 3rd, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for METOPROLOL SUCCINATE?
- What are the global sales for METOPROLOL SUCCINATE?
- What is Average Wholesale Price for METOPROLOL SUCCINATE?
Summary for METOPROLOL SUCCINATE
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 28 |
| Finished Product Suppliers / Packagers: | 44 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 61 |
| Patent Applications: | 2,805 |
| Drug Prices: | Drug price information for METOPROLOL SUCCINATE |
| Drug Sales Revenues: | Drug sales revenues for METOPROLOL SUCCINATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for METOPROLOL SUCCINATE |
| What excipients (inactive ingredients) are in METOPROLOL SUCCINATE? | METOPROLOL SUCCINATE excipients list |
| DailyMed Link: | METOPROLOL SUCCINATE at DailyMed |
Recent Clinical Trials for METOPROLOL SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Rochester | PHASE4 |
| Patient-Centered Outcomes Research Institute | PHASE4 |
| Yihan Chen | PHASE3 |
Pharmacology for METOPROLOL SUCCINATE
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for METOPROLOL SUCCINATE
US Patents and Regulatory Information for METOPROLOL SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visum Pharm | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 207206-003 | Dec 19, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lupin | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 209272-004 | Aug 15, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hetero Labs Ltd Iii | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 205541-003 | Nov 6, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 203894-001 | Mar 23, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
